


10-05-06

IFW

Express Mail Label No. EV 326 984 092 US

Attorney Docket No.: 50450-8032.US02



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: IVERSEN PATRICK L.

APPLICATION No.: 10/719,633

FILED: November 21, 2003

FOR: ANTISENSE ANTIBACTERIAL METHOD
AND COMPOSITION

EXAMINER: MCGARRY, SEAN

ART UNIT: 1635

CONF. No: 3642

**Information Disclosure Statement Within Three Months of
Application Filing or Before First Action – 37 C.F.R. § 1.97(b)**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

A. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the National Stage of an International Application or before the mailing date of a first Office Action on the merits or before the mailing date of a first Office Action on the merits after the filing of a Request for Continued Examination under 37 CFR §1.114, whichever occurs last (37 CFR 1.97(b)(4)). The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

B. Cited Information

- ☒ Copies of references 1-10 are issued patent(s) and published application(s) and are not included (see C.F.R. § 1.98(a)(2)(ii)).
- ☒ Copies of references 11-32 can be found in corresponding U.S. application(s) 09/726,774, filed November 29, 2000, now U.S. patent 6,677,153 issued January 13, 2004 of which this application claims priority under 35 U.S.C. §120, and are not being submitted (see C.F.R. § 1.98(d)).

C. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

D. Fee Payment

No fees are believed due because this Information Disclosure Statement is being filed before the mailing date of the first Office Action. However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

E. Patent Term Adjustment (37 C.F.R. § 1.704(d))

- ☐ The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted,
Perkins Coie LLP


Date: October 4, 2006

Gina C. Freschi
Gina C. Freschi
Registration No. 52,062

Correspondence Address:

Customer No. 22918
Perkins Coie LLP
P.O. Box 2168
Menlo Park, California 94026
(650) 838-4300

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/719,633
				Confirmation Number	3642
				Filing Date	November 11, 2003
				First Named Inventor	Iversen, Patrick L.
				Group Art Unit	1635
				Examiner Name	McGarry, Sean
Sheet 1 of 2	Attorney Docket No. 50450-8032.US02				



U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		NUMBER	Kind Code (if known)			
	1.	5,220,014		Saxena Shailendra et al.	6/15/93	
	2.	5,821,052		Chen Gia-Fen et al.	10/13/98	
	3.	5,977,340		Colote Soudhir et al.	11/2/99	
	4.	6,060,456		Arnold et al.	5/9/00	
	5.	6,133,246		McKay et al.,	10/17/00	
	6.	6,228,579		Zyskind et al.	5/8/01	
	7.	6,239,265		Cook	5/29/01	
	8.	6,495,663		Rothbard	12/17/02	
	9.	6,677,153	B2	Iversen	1/13/04	
	10.	7,049,431	B2	Iversen	5/23/06	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				
	11.	EP	0 892 064	A2	EPO	6/1/98		
	12.	EP	0 894 857	A2	EPO	7/23/98		
	13.	PCT	WO 91 09033		WIPO	6/27/91		
	14.	PCT	WO 98/03533		WIPO	1/29/98		
	15.	PCT	WO 98/32467		WIPO	7/30/98		
	16.	PCT	WO 99/02673		WIPO	1/21/99		

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	17.	Agrawal et al., <i>Tibtech</i> , 14:376-387 (1996).	
	18.	Baker, Pamela J. et al., "Subinhibitory Concentrations of Cefpodoxime Alter Membrane Protein Expression of Actinobacillus actinomycetemcomitans and Enhance Its Susceptibility to Killing by Neutrophils", Antimicrobial Agents and Chemotherapy, pp. 406-412, Feb. 1995.	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/719,633
				Confirmation Number	3642
				Filing Date	November 11, 2003
				First Named Inventor	Iversen, Patrick L.
				Group Art Unit	1635
Examiner Name	McGarry, Sean				
Attorney Docket No.	50450-8032.US02				
Sheet	2	of	2		

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	19.	Branch et al., <i>Trends in Biochem. Sci.</i> , <u>23</u> :45-50 (1998).	
	20.	Filadoro, F., "Bacteria, Antibiotics and the Immune System: A Look at a Classic Triad", <i>Igiene Moderna</i> 104(3), pp. 459-465, 1995 (Abstract Only)	
	21.	Green et al., <i>J. Am. Coll. Surg., Collective Review</i> , pp. 93-105	
	22.	Good et al., <i>Nature Biotechnology</i> , <u>16</u> :355-358 (1998).	
	23.	Good et al., <i>PNAS</i> , <u>95</u> :2073-2076 (1998).	
	24.	Gotfried et al., <i>Clinical Therapeutics</i> , <u>22</u> (1):2-14 (2000).	
	25.	Iversen, Patrick L., "Phosphorodiamidate Morpholino Oligomers", <i>Antisense Drug Technology, Principles, Strategies and Applications</i> , Copyright 2001 by Marcel Dekker, Inc., pp. 375-389.	
	26.	Jayaraman et al., <i>PNAS</i> , <u>78</u> (3):1537-1541 (1981).	
	27.	Jen et al., <i>Stem Cells</i> , <u>18</u> :307-319 (2000).	
	28.	Rahman et al., <i>Antisense Research and Development</i> , <u>1</u> :319-327 (1991).	
	29.	Suzuki, I. et al., "In vivo Activity of Cefbuperazone (T-1982) Against Various Experimental Infections in Mice", <i>Journal of Antibiotics (J. Antibiot.) (Japan)</i> 38/2, pp. 249-258, 1985 (Abstract Only).	
	30.	Summerton et al., <i>Biochim et. Biophys. ACTA</i> , <u>1489</u> :141-158 (1999).	
	31.	Tornqvist, Inga Odenholt et al., "Pharmacodynamic Effects of Subinhibitory Antibiotic Concentrations", <i>Scand J. Infect Dis, Suppl.</i> 74:94-101, 1991.	
	32.	Zak, O. et al., "Correlation of Antibacterial Activities of Antibiotics in vitro and in Animal Models of Infection", <i>Journal of Antimicrobial Chemotherapy</i> 15, Suppl. A, pp. 273-282, 1985.	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	